|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 67:7–30. 2018. View Article : Google Scholar
|
|
2
|
Domvri K, Zarogoulidis P, Darwiche K,
Browning RF, Li Q, Turner JF, Kioumis I, Spyratos D, Porpodis K,
Papaiwannou A, et al: Molecular targeted drugs and biomarkers in
NSCLC, the evolving role of individualized therapy. J Cancer.
4:736–754. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim KW, Myers CJ, Jung DK and Lu B:
NVP-BEZ-235 enhances radiosensitization via blockade of the
PI3K/mTOR pathway in cisplatin-resistant non-small cell lung
carcinoma. Genes Cancer. 5:293–302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hussain S, Benavente SB, Nascimento E,
Dragoni I, Kurowski A, Gillich A, Humphreys P and Frye M: The
nucleolar RNA methyltransferase Misu (NSun2) is required for
mitotic spindle stability. J Cell Biol. 186:27–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li C, Zhang Y, Yang Q, Ye F, Sun SY, Chen
ES and Liou YC: NuSAP modulates the dynamics of kinetochore
microtubules by attenuating MCAK depolymerisation activity. Sci
Rep. 6:187732016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ribbeck K, Groen AC, Santarella R,
Bohnsack MT, Raemaekers T, Köcher T, Gentzel M, Görlich D, Wilm M,
Carmeliet G, et al: NuSAP, a mitotic RanGTP target that stabilizes
and cross-links microtubules. Mol Biol Cell. 17:2646–2660. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kokkinakis DM, Liu X and Neuner RD:
Modulation of cell cycle and gene expression in pancreatic tumor
cell lines by methionine deprivation (methionine stress):
Implications to the therapy of pancreatic adenocarcinoma. Mol
Cancer Ther. 4:1338–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ryu B, Kim DS, DeLuca AM and Alani RM:
Comprehensive expression profiling of tumor cell lines identifies
molecular signatures of melanoma progression. PLoS One. 2:e5942007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gordon CA, Gong X, Ganesh D and Brooks JD:
NUSAP1 promotes invasion and metastasis of prostate cancer.
Oncotarget. 8:29935–29950. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen DT, Nasir A, Culhane A, Venkataramu
C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M, et
al: Proliferative genes dominate malignancy-risk gene signature in
histologically-normal breast tissue. Breast Cancer Res Treat.
119:335–346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu R, Guo CX and Zhou HH: Network-based
approach to identify prognostic biomarkers for estrogen
receptor-positive breast cancer treatment with tamoxifen. Cancer
Biol Ther. 16:317–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cuzick J, Swanson GP, Fisher G, Brothman
AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E,
Foster CS, et al: Prognostic value of an RNA expression signature
derived from cell cycle proliferation genes in patients with
prostate cancer: A retrospective study. Lancet Oncol. 12:245–255.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Zhang W, Yan M, Qiu J, Chen J, Sun
X, Chen X, Song L and Zhang Y: Nucleolar and spindle associated
protein 1 promotes metastasis of cervical carcinoma cells by
activating Wnt/β-catenin signaling. J Exp Clin Cancer Res.
38:332019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Roy S, Hooiveld GJ, Seehawer M, Caruso S,
Heinzmann F, Schneider AT, Frank AK, Cardenas DV, Sonntag R, Luedde
M, et al: microRNA 193a-5p regulates levels of Nucleolar- and
spindle-associated Protein 1 to suppress hepatocarcinogenesis.
Gastroenterology. 155:1951–1966. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bidkhori G, Narimani Z, Hosseini Ashtiani
S, Moeini A, Nowzari-Dalini A and Masoudi-Nejad A: Reconstruction
of an integrated genome-scale co-expression network reveals key
modules involved in lung adenocarcinoma. PLoS One. 8:e675522013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu Z, Wang Y, Xiong J, Cui F, Wang L and
Peng H: NUSAP1 knockdown inhibits cell growth and metastasis of
non-small-cell lung cancer through regulating BTG2/PI3K/Akt
signaling. J Cell Physiol. 235:3886–3893. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kay FU, Kandathil A, Batra K, Saboo SS,
Abbara S and Rajiah P: Revisions to the tumor, node, metastasis
staging of lung cancer (8th edition): Rationale, radiologic
findings and clinical implications. World J Radiol. 9:269–279.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pinheiro C, Longatto-Filho A, Scapulatempo
C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA,
Schmitt F and Baltazar F: Increased expression of monocarboxylate
transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch.
452:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin JX, Xie XS, Weng XF, Qiu SL, Xie JW,
Wang JB, Lu J, Chen QY, Cao LL, Lin M, et al: Overexpression of
IC53d promotes the proliferation of gastric cancer cells by
activating the AKT/GSK3β/cyclin D1 signaling pathway. Oncol Rep.
41:2739–2752. 2019.PubMed/NCBI
|
|
20
|
Wang CJ, Zhou ZG, Holmqvist A, Zhang H, Li
Y, Adell G and Sun XF: Survivin expression quantified by Image
Pro-Plus compared with visual assessment. Appl Immunohistochem Mol
Morphol. 17:530–535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Knutsen A, Adell G and Sun XF: Survivin
expression is an independent prognostic factor in rectal cancer
patients with and without preoperative radiotherapy. Int J Radiat
Oncol Biol Phys. 60:149–155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
animals, . Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press; Washington, DC: 2011, https://www.ncbi.nlm.nih.gov/books/NBK54050/
|
|
24
|
Rhodes DR, Ateeq B, Cao Q, Tomlins SA,
Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE,
Bhojani MS, et al: AGTR1 overexpression defines a subset of breast
cancer and confers sensitivity to losartan, an AGTR1 antagonist.
Proc Natl Acad Sci USA. 106:10284–10289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stewart DJ: Wnt signaling pathway in
non-small cell lung cancer. J Natl Cancer Inst. 106:djt3562014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu K and Zhao YC: MEF2D/Wnt/β-catenin
pathway regulates the proliferation of gastric cancer cells and is
regulated by microRNA-19. Tumour Biol. 37:9059–9069. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
I H and Cho JY: Lung cancer biomarkers.
Adv Clin Chem. 72:107–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han G, Wei Z, Cui H, Zhang W, Wei X, Lu Z
and Bai X: NUSAP1 gene silencing inhibits cell proliferation,
migration and invasion through inhibiting DNMT1 gene expression in
human colorectal cancer. Exp Cell Res. 367:216–221. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu X, Xu B, Yang C, Wang W, Zhong D, Zhao
Z, He L, Hu Y, Jiang L, Li J, et al: Nucleolar and spindle
associated protein 1 promotes the aggressiveness of astrocytoma by
activating the Hedgehog signaling pathway. J Exp Clin Cancer Res.
36:1272017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gulzar ZG, McKenney JK and Brooks JD:
Increased expression of NuSAP in recurrent prostate cancer is
mediated by E2F1. Oncogene. 32:70–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reichert N, Wurster S, Ulrich T, Schmitt
K, Hauser S, Probst L, Götz R, Ceteci F, Moll R, Rapp U and Gaubatz
S: Lin9, a subunit of the mammalian DREAM complex, is essential for
embryonic development, for survival of adult mice, and for tumor
suppression. Mol Cell Biol. 30:2896–2908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y,
Xia F, Shan J, Shen J, Yang Z, et al: Overexpression of the
transcription factor MEF2D in hepatocellular carcinoma sustains
malignant character by suppressing G2-M transition genes. Cancer
Res. 74:1452–1462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu HX, Shi L, Zhang Y, Zhu YC, Bai CX,
Wang XD and Zhou JB: Myocyte enhancer factor 2D provides a
cross-talk between chronic inflammation and lung cancer. J Transl
Med. 15:652017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang R, Zhang Y and Li H:
miR-1244/myocyte enhancer factor 2D regulatory loop contributes to
the growth of lung carcinoma. DNA Cell Biol. 34:692–700. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng
F, Shan J, Chen J, Li F, Liu L, et al: MEF2D transduces
microenvironment stimuli to ZEB1 to promote epithelial-mesenchymal
transition and metastasis in colorectal cancer. Cancer Res.
76:5054–5067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y,
Deng A, Chen J, Wang G, Zhu S and Kang J: Lysine acetyltransferase
GCN5 potentiates the growth of non-small cell lung cancer via
promotion of E2F1, Cyclin D1, and Cyclin E1 expression. J Biol
Chem. 288:14510–14521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li K, Pan J, Wang J, Liu F and Wang L:
MiR-665 regulates VSMCs proliferation via targeting FGF9 and MEF2D
and modulating activities of Wnt/β-catenin signaling. Am J Transl
Res. 9:4402–4414. 2017.PubMed/NCBI
|
|
38
|
Shang S, Hua F and Hu ZW: The regulation
of β-catenin activity and function in cancer: Therapeutic
opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou P, Jiang W, Zhang YJ, Kahn SM,
Schieren I, Santella RM and Weinstein IB: Antisense to cyclin D1
inhibits growth and reverses the transformed phenotype of human
esophageal cancer cells. Oncogene. 11:571–580. 1995.PubMed/NCBI
|
|
40
|
Jiang Q, He M, Ma MT, Wu HZ, Yu ZJ, Guan
S, Jiang LY, Wang Y, Zheng DD, Jin F and Wei MJ: MicroRNA-148a
inhibits breast cancer migration and invasion by directly targeting
WNT-1. Oncol Rep. 35:1425–1432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yue X, Zhao Y, Xu Y, Zheng M, Feng Z and
Hu W: Mutant p53 in cancer: Accumulation, gain-of-function, and
therapy. J Mol Biol. 429:1595–1606. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sankala H, Vaughan C, Wang J, Deb S and
Graves PR: Upregulation of the mitochondrial transport protein,
Tim50, by mutant p53 contributes to cell growth and
chemoresistance. Arch Biochem Biophys. 512:52–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Muller PA, Trinidad AG, Timpson P, Morton
JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT,
Noll JE, et al: Mutant p53 enhances MET trafficking and signalling
to drive cell scattering and invasion. Oncogene. 32:1252–1265.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Buganim Y, Kalo E, Brosh R, Besserglick H,
Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, et
al: Mutant p53 protects cells from
12-O-tetradecanoylphorbol-13-acetate-induced death by
attenuating activating transcription factor 3 induction. Cancer
Res. 66:10750–10759. 2006. View Article : Google Scholar : PubMed/NCBI
|
